Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2023-08-09
- Target Recruit Count
- 6
- Registration Number
- NCT00765765
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 47
- Registration Number
- NCT00751868
- Locations
- 🇮🇹
Azienza Osped.Treviglio - Caravaggio, Treviglio, BG, Italy
🇮🇹Ospedale Civile di Campobasso - A. Cardarelli, Campabasso, CB, Italy
🇮🇹Università Federico II, Napoli, Italy
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 82
- Registration Number
- NCT00741988
- Locations
- 🇺🇸
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
Solid Tumors Using Ixabepilone and Dasatinib
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00717704
- Locations
- 🇺🇸
Washington Cancer Institute, Washington, District of Columbia, United States
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT00672009
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT00637897
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 79
- Registration Number
- NCT00633464
- Locations
- 🇪🇸
Local Institution, Barcelona, Spain
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 762
- Registration Number
- NCT00630032
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇫🇷Centre Hospitalier Docteur Duchenne, Boulogne Sur Mer, France
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 15
- Registration Number
- NCT00627978
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 176
- Registration Number
- NCT00593827
- Locations
- 🇺🇸
Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Central Indiana Cancer Centers, Carmel, Indiana, United States
🇺🇸Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.